Search fresh public links, source activity, and ready-to-use post angles for Car-T.
Fresh curated links around CAR-T are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Chimeric antigen receptor (CAR) therapy is away you harness the specificity potential of antibodies and the killing potential of T cells. You make T cells to express bits of an ant...
In this study the people had been treated with anti-CD20 antibodies and they had no cells when treatment was started and they B cells began to recover by 12 weeks and back to norma...
Researchers at Charité report promising results from the first CAR T-cell trial for treatment-refractory rheumatoid arthritis, with all six patients improving and three achieving s...
Renier Brentjen, an early pioneer of CAR T cell therapy, is working on the next generation of these living drugs that can hopefully treat solid tumors, too.
At 25, Michael Walters had already endured unsuccessful lymphoma treatments in New Zealand. A Melbourne hospital quoted up to US$600,000 for CAR-T therapy. He paid less than half t...
By modulating Notch and T cell receptor signaling, scientists have produced functional CD4+ T cells from iPSCs, potentially advancing scalable, off-the-shelf CAR T therapies. The p...
CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In vivo" production techniques could be one solution.
UCLA scientists engineered ready-made T cells from cord blood stem cells that can hunt solid tumors even when cancer cells hide their main target. T cell receptor therapy, commonly...
Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.
Chimeric antigen receptor T cell therapy has redefined the treatment of multiple myeloma, offering deep and durable remissions to patients whose disease had resisted every conventi...
Researchers have engineered a custom ionizable lipid nanoparticle that delivers CAR-encoding mRNA into human T cells with over 90 percent efficiency, producing potent antitumor act...
Shinshu University Hospital's expertise in CAR T-cell therapy R&D and clinical application will be combined with Teijin Regenet's manufacturing and quality-management expertise...
The immune system is full of T cells that could hunt down and destroy tumors, if they were primed. Now, a UC San Francisco team has invented a way to do this by combining immune ce...
CAR T-cell therapy dramatically reduced disease activity in six people with severe rheumatoid arthritis that had resisted other treatments, with three achieving medication-free rem...
A potentially safer, simpler way to create CAR T cells in the body could bring this powerful therapy to the masses. The post Single CAR T Injection Eases Multiple Sclerosis Symptom...
Predictive cell intelligence can be used to reveal cellular states and emerging cellular trajectories earlier in the manufacturing process and to support more informed bioprocessin...
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post A...
The collaboration will combine technology transfer, clinical and commercial manufacturing, and process optimisation to improve production economics and expand patient access
Colin Sample developed a rare bone marrow failure and then leukemia. But now, he is thriving with his family thanks to CAR T-cell therapy.
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
The partnership marks Cellares’ first collaboration with a cell therapy developer in Asia and will evaluate automated manufacturing of GenomeFrontier’s virus-free CAR T process for...
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.